Variables | Hazard ratio [95% CI] | P value |
---|---|---|
Predictive factors for progression-free survival (PFS) | ||
Afatinib dose (40 mg daily vs. 30 mg daily) | 0.40 [0.11–1.49] | 0.1722 |
Sex (male vs. female) | 4.45 [1.14–17.42] | 0.0322 |
Smoking history (ever smokers vs. never smokers) | 0.19 [0.02–2.24] | 0.1867 |
Number of metastatic sites (≥2 sites vs. ≤1 site) | 8.40 [1.90–37.23] | 0.0051 |
Predictive factors for overall survival (OS) | ||
Performance status while starting afatinib (ECOG ≥2 vs. ECOG ≤1) | 6.01 [1.30–28.21] | 0.0219 |